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Abstract
Background: Some Chinese herbal products (CHPs) may contain aristolochic acid (AA) or may
be adulterated by the herbs suspected of containing AA which is nephrotoxic and carcinogenic.
This study aims to identify the risk and the prescription profile of AA-containing CHPs (AA-CHPs)
in Taiwan.
Methods:  A longitudinal analysis was conducted on a randomly sampled cohort of 200,000
patients using the data from the National Health Insurance (NHI) in Taiwan between 1997 and
2003.
Results: During the 7-year study period, 78,644 patients were prescribed with AA-CHPs; most
patients were females, or middle-aged, or both. A total of 526,867 prescriptions were made to use
1,218 licensed AA-CHPs. Over 85% of the AA-exposed patients took less than 60 g of AA-herbs;
however, about 7% were exposed to a cumulated dose of over 100 g of Radix et Rhizoma Asari
(Xixin), Caulis Akebiae (Mutong) or Fructus Aristolochiae (Madouling). Patients of respiratory and
musculoskeletal diseases received most of the AA-CHP prescriptions. The most frequently
prescribed AA-CHPs Shujing Huoxie Tang,  Chuanqiong Chadiao San and  Longdan Xiegan Tang,
containing Radix Stephaniae Tetrandrae, Radix et Rhizoma Asari and Caulis Akebiae, respectively.
Conclusion: About one-third of people in Taiwan have been prescribed with AA-CHPs between
1997 and 2003. Although the cumulated doses were not large, further actions should be carried
out to ensure the safe use of AA-CHPs.
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Background
Considerable attention to the safe use of Chinese herbal
medicines has been drawn since the reports of nephropa-
thy due to some Chinese herbs [1,2]. The reported neph-
rotoxicity and carcinogenicity of aristolochic acid (AA)
was subsequently corroborated by clinical reports [3-9],
results from animal models [10-12] and the detection of
AA bound DNA adducts in kidney and ureteral tissues
[13-16]. These reports led to the prohibition of all AA-
containing products in many countries and regions, such
as the USA, UK, Canada, Germany, Australia and Taiwan
[13,17-20]. The Bureau of Food and Drug Analysis in Tai-
wan is mandated to regularly monitor AA-containing Chi-
nese herbal products (AA-CHPs) in the market by
quantitative and qualitative analysis.
Substitution of specific AA-containing herbs has been
reported. Caulis Akebiae (Mutong), Radix Stephaniae Tetran-
drae (Fangji) and Radix Aucklandiae (Muxiang) may poten-
tially be substituted by Caulis Aristolochiae Manshuriensis
(Guanmutong) [21], Radix Aristolochiae Fangchi (Guan-
fangji) [22-24] and Radix Aristolochiae (Qingmuxiang)
respectively. Inappropriate uses were reported after the
ban had been imposed [18,25-28]. Containing trace
amounts of AA [29,30], Radix et Rhizoma Asari (Xixin) is
banned [19,31] but still available in Mainland China, Tai-
wan, Japan and Korea [32].
The CHPs currently covered by the National Health Insur-
ance (NHI) of Taiwan do not include raw herbs. Manufac-
tured and marketed as extract products, CHPs are
equivalent to the 'finished herbal products' or 'mixed
herbal products' as defined by the World Health Organi-
zation (WHO) [33]. In terms of safety, AA-CHPs may be
quite different from individual AA herbs because tradi-
tional Chinese medicine formulae that are used to make
AA-CHPs were designed to not only enhance the efficacy
of the herbs but also reduce their toxicity [34,35].
This study aims to determine the prescription profile of
AA-CHPs in Taiwan based on data for the period between
January 1997 and November 2003. The prescription data
for 2004 enable us to determine whether the ban on the
use of AA herbs was complied with in Taiwan [36] where
the high incidence and prevalence rates of chronic kidney
disease were associated with the use of herbal medicines
[37].
Methods
Selection of herbs
AA-CHPs in this study are defined as the Chinese herbal
products that are (1) either suspected of containing AAs
(AA herbs), e.g. Herba Aristolochiae (Tianxianteng), Fructus
Aristolochiae (Madouling) and  Xixin, or (2) likely to be
adulterated by AA herbs, e.g. Fangji, Muxiang and Mutong.
In Taiwan, the ban on some SAA herbs, including Guan-
fangji, Qingmuxiang, Guanmutong, Madouling, and Tianxi-
anteng, took effect on 4 November 2003. However Xixin,
Mutong, Fangji and Muxiang, may still be used if correct
species without adulteration or malnomenclature are
assured. We therefore examined all the CHPs licensed by
the Committee on Chinese Medicine and Pharmacy
(CCMP) between 1997 and 2003, including single herbs
and herbal formulae, to determine whether they include
AA herbs. The inclusion period runs from the start of the
research database (1 January 1997) to one day prior to the
ban on AA-CHPs (3 November 2003). The databases used
in this study were also used in similar studies [38,39].
List of licensed Chinese herbal products
The CCMP list shows that 18,019 CHPs were licensed dur-
ing the study period, of which 9,837 were covered by the
NHI. CHPs in Taiwan can only be prescribed by Chinese
medicine practitioners and CHP prescriptions usually
contain more than one single herb/herbal formula [38].
For simplicity, all CHPs with the same CCMP standard
formulae are classified under the same categories, regard-
less of slight variations among products of different phar-
maceutical companies [40]. For example, there are 46
approved licenses for the formula Duhuo Jisheng Tang.
National Health Insurance reimbursement database
The NHI covers over 96.16% of the population in Taiwan
[41]. Our cohort of 200,000 patients was randomly
selected from all NHI beneficiaries, according to the
methods of Knuth [42] and Park and Miller [43] using
random numbers generated by a program written in Sun
WorkShop C 5.0. Under secure encryption, all reimburse-
ment data of the cohort from 1996 onwards were col-
lected and analyzed. The database contains all
transactions of health care services for the cohort, includ-
ing both Western medicine and Chinese medicine, with
the dates and some details of all outpatient visits, hospi-
talization, diagnoses, prescribed CHPs (dosages, dosage
frequency and prescription duration) and the personal
data of the patients. The database was made available by
the National Health Research Institutes in 2002 and was
widely used by researchers in various fields [44]. The main
datasets used were 'Ambulatory care expenditure by visits',
'Details of ambulatory care orders' and 'Registry for con-
tracted medical facilities'. As the NHI of Taiwan does not
cover the use of Chinese medicine in inpatient services, we
only studied the use of Chinese medicine in outpatient
services. Using the data of 2004, we also studied whether
Chinese medicine practitioners complied with the ban on
AA herbs.
Statistical analysis
Data analysis was undertaken by descriptive statistics,
including the decomposition of the AA herb contents ofChinese Medicine 2008, 3:13 http://www.cmjournal.org/content/3/1/13
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the licensed and prescribed AA-CHP items, AA-CHP pre-
scription rates stratified by patient's gender and age, the
median (plus 5 and 95 percentiles) of cumulated doses of
AA herbs, the population distribution of those who had
been potentially exposed to AA herbs at various dosages,
the frequencies of the disease categories prescribed with
AA-CHPs, the most frequently prescribed herbal formulae
potentially containing AA herbs, and the most common
duration and dosage frequencies of AA-CHP prescrip-
tions. All of the above analyses were performed using the
SAS software package (version 9.1, USA).
Results
Between 1 January 1997 and 3 November 2003, 1,218
(12.38%) AA-CHPs were identified out of the total of
9,837 licensed CHPs, of which the most frequently pre-
scribed were Muxiang (35.3%) and Xixin (30.7%). A total
of 526,867 cases of prescribed and reimbursed AA-CHPs
were recorded (Table 1). Among all the AA-CHPs, Xixin
was the most frequently prescribed (44.7%). The co-exist-
ence of more than two AA herbs was identified in both
licensed and prescribed AA-CHPs, of which Mutong and
Xixin  were the most frequently seen. During the study
period, 105,737 patients (52.9%) sought Chinese medi-
cine treatment on at least one occasion, of which 78,644
were prescribed with AA-CHPs. The AA-exposed popula-
tion demonstrated the prevalence of middle-aged female
patients (Table 2). More than 70% of the patients were
exposed to lower cumulated doses (less than 30 mg) of all
AA herbs in CHPs; about 7% of the patients were pre-
scribed with Xixin, Mutong and Madouling at cumulated
doses of over 100 g (Table 3). Given that the random sam-
ple of this cohort accounts for approximately 1% of the
population of Taiwan, it may be inferred that about
344,300 people were exposed to such high cumulated
doses of Xixin, while about 234,700 people were exposed
to similarly high cumulated doses of Mutong.
The major disease categories often prescribed with AA-
CHPs include respiratory diseases (132,598 visits) and
musculoskeletal/connective diseases (77,153 visits), fol-
lowed by symptoms/signs/ill-defined conditions (68,466
visits), digestive diseases (46,646 visits) and injury/poi-
soning (40,260 visits). Among all AA-CHPs, 90.7% were
in the form of herbal formulae, of which the most fre-
quently prescribed were Shujing Huoxie Tang (containing
Fangji), Chuanqiong Chadiao San (containing Xixin) and
Longdan Xiegan Tang (containing Mutong) (Table 4).
About 97.5% of all AA-CHPs were prescribed for treat-
ment of no more than seven days and the most common
dosage frequency (82.7%) was three times a day. Further-
more, our investigation of the 2004 database found an
alarming number of cases of CHPs containing AA herbs
(Tianxianteng or Madouling) prescribed after the ban was
announced on 4 November 2003. We found a total of 68
records involving the prescription of these herbs to 25
patients by 19 Chinese medicine practitioners (in 19 clin-
ics). Therefore, our estimate was that about 2,760 patients
(= 25*23,000,000* 96.16%/200,000) were prescribed
with the prohibited AA-CHPs at least once during the
study period.
Discussion
This study demonstrated that more than one-third
(39.3%) of the population in Taiwan were prescribed with
AA-CHPs during the study period and that the cumulated
doses of AA-CHPs for each patient may have exceeded 100
Table 1: Distribution frequencies of licensed and prescribed Chinese herbal products potentially containing aristolochic acid, 1997–
2003*
Licensed CHPs Prescribed CHPs
Counts % Counts %
Types of AA herbs included
Tianxianteng 1 0.1 339 0.1
Madouling 18 1.5 1,395 0.3
Xixin 307 25.2 191,297 36.3
Herbs potentially adulterated by AA herbs
Fangji (by Guanfangji) 174 14.3 93,447 17.7
Muxiang (by Qingmuxiang) 409 33.6 107,014 20.3
Mutong (by Guanmutong) 225 18.5 87,073 16.5
≥2 of above herbs
Mutong and Muxiang 17 1.4 2,200 0.4
Mutong and Xixin 63 5.2 44,101 8.4
Muxiang and Xixin 20 . 2 - -
Muxiang, Xixin and Tianxianteng 20 . 2 1 -
Total 1,218 100.0 526,867 100.0
*The table shows the distribution frequencies of licensed and prescribed Chinese herbal products (CHPs) that may potentially contain aristolochic 
acid (AA).Chinese Medicine 2008, 3:13 http://www.cmjournal.org/content/3/1/13
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g (Table 3). Exposure to Xixin and Mutong was the most
extensive. Therefore, it is necessary to monitor the use of
CHPs. Special attention should be drawn to prescriptions
for patients suffering from respiratory and/or muscu-
loskeletal diseases and to the herbal formulae with AA
herbs (Table 4).
There are a few major limitations to this study. Firstly, the
study was based upon the NHI reimbursement data. Spe-
cific information is not available for causal studies or
inference. Secondly, different pharmaceutical companies
may obtain their herbs from different sources which may
have different degrees of AA herb adulterations. The esti-
mation of cumulated AA doses may be inaccurate.
Thirdly, this study did cover the consumption of medici-
nal herbs purchased directly from the market. Therefore
our estimate does not represent all consumption of AA
herbs in Taiwan.
Conclusion
This study showed a prescription profile of AA-CHPs in
Taiwan between 1997 and 2003 based on the NHI reim-
bursement data, including an estimate of the total
amount of AA herbs consumed and the target population
requiring continuous monitoring. Moreover, this study
revealed the NHI prescription of some banned AA-CHPs.
Abbreviations
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Table 2: Prescription frequencies of Chinese herbal products (by gender, age and types of herbs), 1997–2003*
Herbal products Gender Age (years)
Male Female <12 12–18 19–34 35–59 60–75 ≥76
Any CHPs 35.4 41.8 11.1 7.3 23.6 26.5 7.2 1.6
AA-CHPs 25.9 31.6 6.8 5.8 17.6 20.6 5.6 1.2
Types of AA herbs included
Xixin 14.8 20.2 4.9 3.1 9.8 12.7 3.7 0.8
Madouling 0.2 0.3 0.1 -- 0.1 0.2 0.1 --
Tianxianteng -- -- -- -- -- -- -- --
Herbs potentially adulterated by AA herbs
Fangji 11.5 13.6 0.8 2.1 7.6 11.0 3.0 0.6
Muxiang 10.3 14.7 2.7 2.5 7.9 9.2 2.2 0.5
Mutong 10.8 14.4 3.3 2.4 7.6 9.2 2.2 0.4
*The prescription frequencies (per 1,000 person-years) of Chinese herbal products (CHPs) are stratified by gender, age and the types of AA 
containing herbs (AA herbs) or those potentially adulterated by AA herbs.
Table 3: Distribution frequencies* of Chinese herbal product prescriptions potentially containing aristolochic acid (by cumulated 
doses), 1997–2003
Herbal product Cumulated dose (g)
Median (90% CI#)
No. of patients Percentages (%) of patients with various cumulated doses of AA herbs
<15 g 16–30 g 31–60 g 61–100 g 101–150 g >150 g
Types of AA herbs included
Xixin 12.6 (1.5–128.5) 47,869 54.1 18.6 13.6 6.4 3.3 4.0
Tianxianteng 10.5 (0.03–87.0) 110 66.0 19.4 2.9 7.8 1.9 1.9
Madouling 21.0 (4.0–120.0) 665 36.0 29.1 19.7 7.5 4.3 3.4
Herbs potentially adulterated by AA herbs
Fangji 6.0 (1.1–50.8) 34,462 77.8 12.0 6.2 2.2 0.9 1.0
Muxiang 8.0 (1.2–70.0) 34,195 69.1 15.9 8.8 3.2 1.6 1.5
Mutong 14.0 (1.8–124.4) 34,399 51.8 19.9 14.6 6.7 3.2 3.8
*Distribution frequency refers to the number of patients who have been prescribed with Chinese herbal products that may potentially contain 
aristolochic acid (AA).
#90% CI: 90% confidence intervalChinese Medicine 2008, 3:13 http://www.cmjournal.org/content/3/1/13
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